ArticleInternational journal of cancer2026
Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Regional Pathology-Detection Trends in High-Grade Cervical Lesions and Cervical Squamous Cell Carcinoma Among Women Aged 40-69 Years in Northern Norway, 1998-2025.Diagnostics (Basel, Switzerland) · 2026Article
- Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regular audits are essential for monitoring and evaluation of cervical screening. We audited the Swedish cervical screening program during the transition to HPV-based screening using a registry-based cohort design. In total, 5689 consecutive, confirmed cases of invasive cervical cancer between 2012 and 2022 were retrieved from the Swedish Quality Register for Gynecological Cancer. Their screening history, screening status, invitations to cervical screening, all diagnoses in screening cytology and HPV genotypes were retrieved from the Swedish National Cervical Screening Registry. Furthermore, all cancer cases during 2018-2022 were classified according to their screening history and the age-standardized cervical cancer incidence rate stratified by screening history and calendar year was calculated among the cohort of all women in Sweden ages 29-84. Non-participation remains the main process related history with high risk of cancer (cervical cancer incidence rate, IR, among non-attenders was 33.9 [95% confidence intervals, 95% CI, 28.2-39.5] per 100,000 person-years, /100,000PY, representing 31% of cases in 2022). The cervical cancer IR after negative cytology increased with calendar time (IR = 5.5 [95% CI, 4.1-6.8]/100,000PY in 2012 and 11.5 [8.1-14.9]/100,000PY in 2022) and was high after a positive HPV test followed by negative cytology triage (IR = 56.7 [39.9-73.6] in 2022). In conclusion, this comprehensive audit has identified a decreasing protection by the screening test under discontinuation (cytology) and that the performance as a triage test after HPV-testing is unsatisfactory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.